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Abstract: Designing efficient recombinant mucosal vaccines against enteric diseases is still a 
major challenge. Mucosal delivery of recombinant vaccines requires encapsulation in potent immu-
nostimulatory particles to induce an efficient immune response. This paper evaluates the capacity 
of β-glucan microparticles (GPs) as antigen vehicles and characterizes their immune-stimulatory 
effects. The relevant infectious antigen FedF was chosen to be loaded inside the microparticles. 
The incorporation of FedF inside the particles was highly efficient (roughly 85%) and occurred 
without antigen degradation. In addition, these GPs have immunostimulatory effects as well, 
demonstrated by the strong reactive oxygen species (ROS) production by porcine neutrophils 
upon their recognition. Although antigen-loaded GPs still induce ROS production, antigen loading 
decreases this production by neutrophils for reasons yet unknown. However, these antigen-loaded 
GPs are still able to bind their specific β-glucan receptor, demonstrated by blocking complement 
receptor 3, which is the major β-glucan receptor on porcine neutrophils. The dual character of these 
particles is confirmed by a T-cell proliferation assay. FedF-loaded particles induce a significantly 
higher FedF-specific T-cell proliferation than soluble FedF. Taken together, these results show 
that GPs are efficient antigen carriers with immune-stimulatory properties.
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Introduction
Mucosal vaccination is the most efficient way to protect human and animals against 
enteric infections. However, the development of effective mucosal vaccine subunits 
encounters multiple challenges, such as antigen damaging and limited immunogenicity.1–4 
The encapsulation of antigens in microparticles is a promising approach to overcome 
these problems, as they can protect the antigens against degradation as well as carry 
potent adjuvants or immune modulators to enhance the immunogenicity.5–7 Frequently 
used particle systems for oral immunization are those based on poly(lactic-co-glycolic 
acid); however, low antigen encapsulation efficiency and antigen degradation during 
their formation limit their use in commercial vaccines.8 On the contrary, β-glucan 
microparticles (GPs) are emerging microparticles known for their safety, immunoge-
nicity, and high antigen encapsulation efficiency.9–18 These promising antigen carriers 
are derived from the cell wall of Saccharomyces cerevisiae (Baker’s yeast) and are 
composed of .85% β-1,3-d-glucan polymers (β-glucans), ~2% chitin, and ,1% lipids 
and proteins, with the rest being mostly ash and moisture.15 The main component of these 
particles, the β-glucans, is a “microbe-associated molecular pattern”, which is very inter-
esting in vaccine development for its immunostimulating characteristics.19,20 We have 
previously reported that particulate β-glucans are mainly recognized by complement 
receptor 3 (CR3) on porcine innate immune cells and require the signaling molecule 
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FAK to carry out their immunostimulatory responses.21 
However, the receptor involved in the immunostimulat-
ing characteristics of GPs is not yet known. Many articles 
have described the strong potency of these GPs in eliciting 
durable immune responses in mice.9,10,14,22,23 Incubation of 
mouse bone marrow–derived dendritic cells with ovalbumin 
(OVA)-loaded GPs resulted in phagocytosis, upregulation 
of maturation markers, rapid proteolysis of OVA, and pro-
liferation of OVA-reactive transgenic CD8+ OT-I and CD4+ 
OT-II T-cells.14 However, the immunological effect of these 
particles on porcine innate immune cells has not been inves-
tigated yet. Moreover, besides the incorporation of model 
antigens, no clinically relevant antigens were incorporated 
in these GPs. We have incorporated FedF, the tipadhesin of 
F18 fimbriae, inside the particles, since this antigen is one of 
the most important virulence factors of F18+ Escherichia coli. 
E. coli carrying the F18 fimbriae colonizes the small intestine 
of pigs and cause postweaning diarrhea (enterotoxigenic 
E. coli [ETEC]) and edema disease (Shiga toxin-producing 
E. coli [STEC]) in pigs, resulting in economic losses to the 
pig production industry.24 The bacteria adhere to the intestinal 
epithelial surface with their fimbriae and produce enterotox-
ins, which induce secretion of electrolytes and water. Porcine 
ETEC strains can produce five fimbrial types (F4, F18, F41, 
F5, and F6), of which F4 and F18 are most frequently asso-
ciated with ETEC-induced diarrhea.25 The F18 fimbriae are 
polymeric proteins composed of several subunits: FedA is 
the structural subunit, while FedF is the tipadhesin mediat-
ing the binding of the bacteria to the epithelium. The FedF 
subunit of F18 fimbriae is located in a dedicated single-copy 
adhesin at the distal tip of the fimbriae.26 Tipadhesins are usu-
ally composed of two immunoglobulin (Ig)-like domains: an 
N-terminal lectin or receptor binding module and a C-terminal 
pilin. As it needs a complementary β-strand from the FedE 
subunit, using donor strand complementation is necessary to 
achieve a stable recombinant expression of FedF.27 To protect 
pigs against F18+ ETEC infections, local intestinal immunity 
is required. However, oral immunization with F18 fimbriae 
does not elicit protection in a piglet model, probably due to the 
presence of immunodominant epitopes in the FedA subunit.28 
We reasoned that oral immunization of piglets with purified 
FedF subunit would enable induction of protective immunity, 
but only if FedF is encapsulated inside microparticles so 
asto deliver higher amounts of antigens to the gut-associated 
lymphoid tissue and to induce strong immune responses by 
mimicking pathogen dimensions.
So, we incorporated FedF inside GPs for oral administra-
tion to induce intestinal FedF-specific antibody responses. 
In this study, we investigated the capacity of these GPs 
as both antigen vehicles and immunostimulants. Porcine 
immune cells were used as the translational model, because 
β-glucan recognition and signaling in porcine innate immune 
cells is closer related to humans than murine cells.21,29,30
Experimental section
generation of FedF
FedF was generated using the method of De Kerpel et al.27 
Briefly, the fedF
15-165
 gene from F18 E. coli 107/86 strain 
was cloned in the pDEST14 vector under a T7 promo-
tor. The gene was C-terminal truncated and then trans-
formed into E. coli strain C43 (DE3). The C43 (DE3) 
cells were grown, induced with 1 mM isopropyl β-d-1-
thiogalactopyranoside, and incubated for 2 hours. Cells 
were subjected to osmotic shock and the periplasmic extract 
was loaded onto a Source 3S column (Amersham plc, 
Amersham, UK) for cation exchange in 20 mM Tris (pH 
7.5). Proteins were eluted with 140 mM NaCl and further 
purified using gel filtration on a Superdex-75HR column 
in 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (pH 7.0) and 150 mM NaCl. Finally, the protein was 
dialyzed against 0.9% saline.
Development of gPs and protein 
encapsulation
To generate GPs, S. cerevisiae (Baker’s yeast) was treated 
with alkali and acid and dried at 20°C–25°C following alcohol 
and acetone washing steps.14,15 The resulting GPs were hol-
low and porous biomimetic 2–5 µm particles consisting 
of .85% β-1,3-d-glucan polymers (β-glucans), ~2% chitin, 
and ,1% lipids and proteins, with the rest being mostly 
ash and moisture.15 Subsequently, these GPs were loaded 
with FedF as previously described.14 Briefly, 10 mg of dry 
GPs were swollen with 5 mg FedF dissolved in 0.9% saline 
(1.25 mL) for 2 hours at 4°C, followed by lyophilization. 
These dry GP-FedF preparations were reswollen with 
300 µL aqua dest to maximize FedF diffusion into the GPs. 
Upon relyophilisation, FedF was trapped inside the GPs by 
adding 350 µL of 25 mg/mL transfer RNA (derived from 
torula yeast) in Tris, EDTA, and NaCl buffer (50 mM Tris 
HCl with 2 mM ethylenediaminetetraacetic acid and 0.15 M 
NaCl, pH 8.2) for 30 minutes at 50°C. To complete the 
complexation reaction, another 500 µL of 10 mg/mL trans-
fer RNA was added to the particles. The suspension was 
centrifuged, washed four times in 0.9% saline, and stored 
at -20°C (2.5 mg/mL).14 To calculate the amount of FedF 
trapped inside the GPs, the unbound FedF protein in the wash 
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fractions was measured by a bicinchoninic acid assay against 
a bovine serum albumin standard (0.05–1 mg/mL).
Western blotting
Incorporation of FedF inside the particles was confirmed 
using a protein gel electrophoresis after digesting the GPs 
with β-1,3-d-glucanase from Helix pomatia (Sigma-Aldrich 
Co., St Louis, MO, USA). FedF-loaded GPs were first incu-
bated in β-glucanases (1 mg/mL) diluted in 150 mM sodium 
acetate buffer (Sigma-Aldrich Co.) for 24 hours at 37°C. 
Proteins, released in the supernatants, were separated via 
sodium dodecyl sulfate–polyacrylamide gel electrophoresis 
consisting of a 12% separating gel and a 4% stacking gel. 
The gels were prepared by dissolving 30% acrylamide in 
Tris (pH 8.8), 10% sodium dodecyl sulfate, 10% ammonium 
persulfate, and tetramethylethylenediamine. To load the 
samples, the proteins were mixed in equal volume ratios with 
the loading buffer containing β-mercaptoethanol and heated 
at 100°C for 5 minutes. Electrophoresis was performed at 
28 mA for 1 hour. After separation, the proteins were trans-
ferred to a 0.45 µm polyvinylidene fluoride membrane (GE 
Healthcare, Stockholm, Sweden) at 40 V for 2 hours. Next, 
the membrane was blocked (1 hour at room temperature) with 
5% milk powder diluted in phosphate-buffered saline +0.1% 
Tween®20 (Sigma-Aldrich Co.) to prevent antibodies from 
nonspecifically binding to the membrane. Monoclonal 
anti-mouse FedF-specific antibodies (10 µg) were added 
overnight to the blot, followed by horseradish peroxidase-
conjugated rabbit anti-mouse IgG (1/2,000; Dako, Denmark 
A/S Glostrup, Denmark) for 1 hour at room temperature. The 
bands were visualized using enhanced chemiluminescence 
(ECL) Western blotting substrate (Thermo Fisher Scientific, 
Waltham, MA, USA) and ChemiDOC™ MP imaging system 
(Bio-Rad Laboratories Inc., Hercules, CA, USA).
Oxidative burst by porcine neutrophils
All animal experiments were approved by the animal care 
and ethics committee of the Faculty of Veterinary Medicine, 
Ghent University (Gent, Belgium; EC2013/62). Piglets 
(between 4 and 20 weeks old) were housed under standard 
conditions as blood donors. Peripheral blood was collected 
on heparin from the jugular vein of four pigs. Subsequently, 
neutrophils were isolated by density gradient centrifugation 
on a discontinuous Percoll gradient (68% and 75%; GE 
Healthcare) as described previously.31 To examine the immu-
nostimulating characteristics of the particles, the ability of the 
GPs to induce an oxidative burst response by porcine neu-
trophils was investigated. The production of reactive oxygen 
species (ROS) was measured by the chemiluminescence 
assay described by Donne et al32 with some modifications. 
Neutrophils were seeded in a 96-well plate at 2.0×105 cells/
well in Roswell Park Memorial Institute (RPMI) without 
phenol red. The plates were incubated at 37°C for 2 hours in 
a humidified atmosphere with 5% CO
2
 to allow the cells to 
adhere to the plastic surface. Subsequently, the supernatant 
was replaced by 175 µL luminol (0.5 mM). After 5 minutes 
of background measurement at 37°C, 25 µL of the indicated 
GPs (400, 200, or 100 µg/mL) were added. Stimulation of 
the cells with phorbol myristate acetate (PMA; 50 µg/mL) 
was used as a positive control. ROS production was then 
measured during 120 minutes in the integration mode. All 
stimulations were performed in duplicate. The ROS produc-
tion is expressed as relative light units.
Determination of the β-glucan receptor 
in porcine neutrophils
To analyze the role of dectin-1 and CR3 in the immunostimu-
lating characteristics of these GPs, the production of ROS by 
neutrophils was measured using the chemiluminescence assay 
(as already described) with some modifications. Neutrophils 
were seeded in a 96-well plate at 2.0×105 cells/well. The plates 
were incubated at 37°C for 2 hours in a humidified atmosphere 
with 5% CO
2
 to allow the cells to adhere to the plastic surface. 
Then, the cells were pretreated with the β-glucan receptor 
inhibitors for 1 hour at 37°C. To inhibit dectin-1, laminarin 
(1 mg/mL) was added to the cells. To inhibit CR3-mediated 
responses, monoclonal antibodies (mAbs; mouse IgG
1
 iso-
types) against CD18 (5 µg/mL) and CD11R3 (15 µg/mL) 
(Bio-Rad Laboratories Inc.) were added. These antibodies 
were dialyzed against phosphate-buffered saline to remove 
sodium azide. An isotype-matched mAb control (IgG
1
) was 
added to the cells to measure background inhibition. Sub-
sequently, luminol was added to the cells (0.5 mM diluted 
in Hanks’ balanced salt solution + Ca2+ Mg2+), and, after 
5 minutes of background measurement at 37°C, 25 µL of GPs 
(200 µg/mL) was added. Stimulation of the cells with PMA 
(50 µg/mL) was used as a positive control. ROS production 
was then measured after 120 minutes in the integration mode. 
All stimulations were performed in duplicate. ROS produc-
tion is expressed as relative light units.
generation of monocyte-derived 
dendritic cells
Peripheral blood monomorphonuclear cells (PBMCs) were 
isolated by density gradient centrifugation on Lymphop-
rep (Nycomed Pharma AS, Thermo Fisher Scientific). 
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Furthermore, monocytes were enriched from the PBMCs 
to a purity of .95% by positive immunomagnetic bead 
selection (MACS; Miltenyi Biotec, Bergisch Gladbach, 
Germany) using the anti-SIRPα monoclonal antibody 
(clone 74-12-15a33). These cells were seeded in a 24-well 
plate at a density of 0.5×106 cells/mL in monocyte-derived 
dendritic cell (MoDC) medium (Dulbeccos’ Modified 
Eagle Medium supplemented with 10% fetal calf serum, 
1% penicillin–streptomycin, recombinant porcine 1/200 
GM-CSF34 and 5 ng/mL IL-4). After 3 days incubation 
at 37°C in a humidified atmosphere at 5% CO
2
, fresh 
medium supplemented with GM-CSF and IL-4 at the same 
concentration to cells was added to generate MoDCs as 
previously described.35
antigen presentation assay
To investigate whether incorporation of FedF inside the 
particles is necessary to induce FedF-specific cellular 
immune responses, a coculture of MoDCs and CD6+ T-cells 
was set up. So, T-cells isolated from pigs immunized intra-
muscularly with 250 µg purified FedF in incomplete Freund’s 
adjuvant were used.36 CD6+ T-cells were enriched from 
PBMCs to a purity of .95% by positive immunomagnetic 
selection with the α-CD6 mAb (IgG
1
, clone a38b237) and goat 
anti-mouse microbeads (MACS, Miltenyi Biotec). MoDCs 
were stimulated with 8 µg FedF or FedF-loaded GPs (8 µg 
FedF encapsulated) for 24 hours or left untreated (control). 
These stimulated MoDCs were subsequently cocultured at 
titrated numbers with 1.0×105 autologous CD6+ T-cells for 
5 days, and then the [3H] methyl-thymidine (1 µCi/well; 
Amersham plc) incorporation (18 hours) was measured 
using a β-scintillation counter (PerkinElmer Inc., Waltham, 
MA, USA).
statistics
Data are presented as the mean ± standard error of the mean. 
Data were analyzed with GraphPad Prism 5 (GraphPad 
Software, Inc., La Jolla, CA, USA) using the paired t-test 
for comparison of two data and using a repeated measures 
analysis of variance (post hoc: Tukey) for comparison 
of multiple data sets. Data were considered significant at 
P,0.05.
Results and discussion
Efficient loading of FedF inside GPs
To assess if loading of FedF into GPs affects the antigenic-
ity, we performed Western blotting. FedF was incorporated 
inside the GPs with a loading efficiency of 84.53%±2.89%, 
thereby confirming the high loading efficiency of the GPs 
(Figure 1A). Furthermore, we examined by gel electropho-
resis the correct incorporation of FedF inside the particles. 
Therefore, we first destroyed the β-glucan particles by 
β-glucanases, after which the supernatants with the released 
antigens were loaded on a protein gel electrophoresis and 
detected by monoclonal FedF-specific antibodies (clone 
IMM0438). Figure 1B illustrates the protein FedF in lane 1 
Figure 1 FedF was efficiently incorporated inside GPs.
Notes: (A) The loading efficiency of FedF inside GPs was determined by BCA. Therefore, the unbound FedF protein in the wash fractions was measured by BCA against a 
Bsa standard (0.05–1 mg/ml). (B) FedF incorporation inside the gPs was analyzed by Western blotting after digesting the particles with β-glucanases. FedF was detected 
with specific monoclonal antibodies against FedF. Lane 1 illustrates FedF, while the FedF released from the GPs upon digestion is shown in lane 2.
Abbreviations: gPs, β-glucan microparticles; Bca, bicinchoninic acid assay; Bsa, bovine serum albumin.
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and the FedF released from the digested GPs in lane 2. As 
shown, both FedF and the released FedF migrate near the 
expected molecular weight of 18 kDa. No degradation is 
visible, indicating the correct incorporation of FedF inside 
the particles. On the basis of these results, we conclude that 
FedF is efficiently incorporated inside the particles.
FedF-loaded gPs still possess  
immune-stimulatory effects
To assess the effect of antigen loading on the inherent 
immunostimulating characteristics of the GP, we determined 
the oxygen radical production of porcine neutrophils after 
stimulation with antigen-loaded particles. Figure 2 demon-
strates that FedF-loaded GPs possess immune-stimulatory 
effects. Interestingly, hollow GPs could stimulate ROS 
production by neutrophils more than antigen-loaded particles, 
indicating that antigen loading partially masks the β-glucans 
of the particles from recognition by their receptors, dectin-1, 
and CR3.21
The immune-modulatory effects of gPs 
are mainly mediated by binding to the 
α-subunit of cr3
We further investigated which β-glucan receptor is involved 
in the particle-induced activation of porcine neutrophils. 
As shown in Figure 3, the GPs-induced ROS production 
by neutrophils was significantly inhibited in the presence 
of anti-CD11R3 as compared to its isotype-matched 
control. In contrast to the α-subunit of CR3, the ability of 
CD18-specific mAbs to block ROS production by porcine 
neutrophils was negligible (β-subunit of CR3). Interestingly, 
blocking dectin-1 by laminarin decreased ROS production 
as well, albeit not as much as CD11R3-specific mAbs. 
Although incorporation of antigens inside the particles seems 
to influence the recognition of GPs by dectin-1, CD11R3 is 
still the most important receptor for the GP-induced ROS 
production in porcine neutrophils.
T-cell proliferation is significantly 
increased when FedF is incorporated 
inside gPs
To assess whether GPs could serve as an immune stimulatory 
antigen delivery system, we investigated the FedF-specific 
T-cell proliferation after stimulation of MoDCs with 
FedF-GPs. As illustrated in Figure 4, FedF-loaded GPs 
promoted the antigen presentation capacity of MoDCs 
Figure 2 FedF-loaded gPs still possess their adjuvant function.
Notes: Neutrophils (2×105 cells) were stimulated with gPs at the indicated 
concentrations. rOs production was determined via chemiluminescence. Data are 
shown as the mean rlU ± seM of four pigs. *P,0.01.
Abbreviations: gPs, β-glucan microparticles; rlU, relative light units; rOs, reactive 
oxygen species; seM, standard error of the mean.
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to porcine CD6+ T-cells as compared to immature and 
FedF-stimulated MoDCs. Surprisingly, FedF stimulation of 
dendritic cells did not elicit T-cell proliferation, suggesting 
that FedF has an inhibitory effect on MoDCs. Clearly, the 
encapsulation of FedF inside immunostimulatory particles 
avoids this inhibitory effect and hence is necessary to induce 
T-cell proliferation.
Conclusion
GPs are emerging particles known for their high antigen-
loading capacity and safety. In this study, we evaluated the 
incorporation of a clinically relevant infectious disease antigen 
FedF, the tipadhesin of F18 fimbriae, inside these particles. 
The results clearly demonstrate that FedF is incorporated 
intact inside the particles with a high loading efficiency 
(84.5%). Besides antigen carrier activity, these particles are 
able to stimulate the innate immune system by binding to the 
α-subunit of CR3. To confirm the duality of these particles, we 
demonstrated in a T-cell proliferation assay that FedF inside the 
particles is processed by MoDCs and subsequently presented 
to T-cells, resulting in their activation and proliferation. Taken 
together, FedF-loaded GPs are promising vaccine candidates in 
the protection of pigs against F18+ ETEC and STEC infections, 
and this study motivates exploring this vaccine in vivo.
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